Claims
- 1. A substituted basic 2-aminotetralin of the formula ##STR124## wherein R.sup.1 represents hydrogen or lower alkyl,
- R.sup.2 represents hydrogen, lower alkyl, lower alkylcarbonyl, or benzoyl,
- c denotes a number 0, 1 or 2,
- d denotes a number 2 or 3,
- X denotes oxygen or the group NR.sup.5,
- where
- R.sup.5 represents hydrogen, or represents lower alkyl which is optionally substituted by hydroxyl or amino, or represents phenyl, benzyl, lower alkoxycarbonyl, lower alkylsulphonyl or carbamoyl,
- 2. A substituted basic 2-aminotetralin or salt according to claim 1, wherein
- R.sup.1 represents hydrogen or methyl,
- R.sup.2 represents hydrogen, methyl, ethyl, propyl, isopropyl, acetyl or propionyl,
- c denotes a number 1 to 2,
- d denotes the number 2,
- X denotes the NR.sup.5 group,
- where
- R.sup.5 represents hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, phenyl, benzyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, methylsulphenyl, ethylsulphonyl or carbamoyl.
- 3. A compound according to claim 1, wherein such compound is 2-(1-ethoxycarbonypiperidin-4-yl-)amino-8-methoxy-1,2,3,4-tetrahydronaphthalene of the formula ##STR125## or its salt.
- 4. A compound according to claim 1, wherein such compound is 8-methoxy-2-(1-methylpiperidin-4-yl-)amino-1,2,3,4-tetrahydronaphthalene of the formula ##STR126## or its salt.
- 5. A composition for treatment of a disorder of the central nervous system comprising an amount effective therefor of a compound or salt according to claim 1 and a physiologically acceptable diluent.
- 6. A unit dose of of a composition according to claim 5 in the form of a tablet, ampule or capsule.
- 7. A method of treating a patient suffering from
- a disorder of the central nervous system caused by a disturbance of the serotoninergic system,
- which comprises administering to such patient an amount effective therefor of a compound or salt according to claim 16.
- 8. The method according to claim 7, wherein such compound is
- 2-(1-ethoxycarbonypiperidin-4-yl-)amino-8-methoxy-1,2,3,4-tetrahydronaphthalene, and
- 8-methoxy-2-(1-methylpiperidin-4-yl-)amino-1,2,3,4-tetrahydronaphthalene,
- or its salt.
Priority Claims (2)
Number |
Date |
Country |
Kind |
3642192 |
Dec 1986 |
DEX |
|
3718317 |
Jun 1987 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 130,373, filed Dec. 8, 1987, now U.S. Pat. No. 4,880,802 issued Apr. 14, 1989.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4707497 |
Cecchi et al. |
Nov 1987 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
0026848 |
Apr 1981 |
EPX |
0161604 |
Nov 1985 |
EPX |
2323388 |
Apr 1977 |
FRX |
2391189 |
Dec 1978 |
FRX |
Non-Patent Literature Citations (3)
Entry |
Christova et al., CA 94: 30049t, CA 90: 87114t. |
Uvanov et al., CA 88: 89624u. |
Chemical Abstracts, vol. 106, Feb. 2, 1987, No. 5, p. 94, 106: 28103s, Emerit et al., "Irreversible blockade of central 5-HT1A receptor . . .". |
Divisions (1)
|
Number |
Date |
Country |
Parent |
130373 |
Dec 1987 |
|